Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.
Antibodies
COVID-19
Obesity
SARS-CoV-2
Serum titre
Vaccine
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
23
02
2021
revised:
28
04
2021
accepted:
10
05
2021
pubmed:
11
6
2021
medline:
11
6
2021
entrez:
10
6
2021
Statut:
ppublish
Résumé
Literature data suggests that age, gender and body mass index (BMI) could be associated with difference in immune responses to vaccines. The first goal of the study was to analyze the antibody titre seven days after the second dose of BNT162b2 vaccine in a group of 248 healthcare workers (HCWs). The second goal was to analyze how antibody titre changes in correlation with age, gender, BMI and hypertension. An immunogenicity evaluation was carried out among HCWs vaccinated at the Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy. All HCWs were asked to be vaccinated by the Italian national vaccine campaign at the beginning of 2021. 260 vaccinated HCWs were enrolled in the study. All eligible participants were assigned to receive the priming dose in two weeks' time and the booster dose exactly 21 days thereafter. Blood and nasopharyngeal swabs were collected at baseline and 7 days after second dose of vaccine. Quantitative measurements of IgG antibodies against S1/S2 antigens of SARS-CoV-2 were performed with a commercial chemiluminescent immunoassay. Presence of SARS-Cov-2 in nasopharyngeal swab was determined by commercial RT-PCR testing. 248 HWCs were analyzed, 158 women (63.7%) and 90 men (36.3%). After the second dose of BNT162b2 vaccine, 99.5% of participants developed a humoral immune response. The geometric mean concentration of antibodies among the vaccinated subjects after booster dose (285.9 AU/mL 95% CI: 249.5-327.7) was higher than that of human convalescent sera (39.4 AU/mL, 95% CI: 33.1-46.9), with 99.5% of HCW developed a humoral immune response and female and young participants seem to have an increased capacity to mount humoral immune responses. BMI and hypertension seem not associated with difference in immune response to the vaccine. None.
Sections du résumé
BACKGROUND
BACKGROUND
Literature data suggests that age, gender and body mass index (BMI) could be associated with difference in immune responses to vaccines. The first goal of the study was to analyze the antibody titre seven days after the second dose of BNT162b2 vaccine in a group of 248 healthcare workers (HCWs). The second goal was to analyze how antibody titre changes in correlation with age, gender, BMI and hypertension.
METHODS
METHODS
An immunogenicity evaluation was carried out among HCWs vaccinated at the Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy. All HCWs were asked to be vaccinated by the Italian national vaccine campaign at the beginning of 2021. 260 vaccinated HCWs were enrolled in the study. All eligible participants were assigned to receive the priming dose in two weeks' time and the booster dose exactly 21 days thereafter. Blood and nasopharyngeal swabs were collected at baseline and 7 days after second dose of vaccine. Quantitative measurements of IgG antibodies against S1/S2 antigens of SARS-CoV-2 were performed with a commercial chemiluminescent immunoassay. Presence of SARS-Cov-2 in nasopharyngeal swab was determined by commercial RT-PCR testing.
FINDINGS
RESULTS
248 HWCs were analyzed, 158 women (63.7%) and 90 men (36.3%). After the second dose of BNT162b2 vaccine, 99.5% of participants developed a humoral immune response. The geometric mean concentration of antibodies among the vaccinated subjects after booster dose (285.9 AU/mL 95% CI: 249.5-327.7) was higher than that of human convalescent sera (39.4 AU/mL, 95% CI: 33.1-46.9), with
INTERPRETATION
CONCLUSIONS
99.5% of HCW developed a humoral immune response and female and young participants seem to have an increased capacity to mount humoral immune responses. BMI and hypertension seem not associated with difference in immune response to the vaccine.
FUNDING
BACKGROUND
None.
Identifiants
pubmed: 34109307
doi: 10.1016/j.eclinm.2021.100928
pii: S2589-5370(21)00208-X
pmc: PMC8177433
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100928Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
All authors declare no conflict of interest to disclose.
Références
Vaccine. 2018 Aug 28;36(36):5350-5357
pubmed: 28774561
Arch Intern Med. 2008 Dec 8;168(22):2405-14
pubmed: 19064822
Obesity (Silver Spring). 2016 Mar;24(3):615-25
pubmed: 26857091
Annu Rev Cell Dev Biol. 2017 Oct 6;33:577-599
pubmed: 28992436
Nat Med. 2011 Feb;17(2):179-88
pubmed: 21217695
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Cell Metab. 2021 Mar 2;33(3):479-498
pubmed: 33529600
Front Immunol. 2019 Feb 27;10:180
pubmed: 30873150
Vaccine. 2010 Nov 29;28(51):8077-84
pubmed: 20974306
JAMA. 1985 Dec 13;254(22):3187-9
pubmed: 2933532
Blood. 2011 Aug 4;118(5):1294-304
pubmed: 21562046
Int J Obes (Lond). 2012 Aug;36(8):1072-7
pubmed: 22024641
Vaccine. 2014 Feb 12;32(8):979-83
pubmed: 24394442
Blood. 2011 Aug 4;118(5):1305-15
pubmed: 21543762
J Heart Valve Dis. 1998 Sep;7(5):548-55
pubmed: 9793855
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):869-74
pubmed: 24367114
Nature. 2020 Oct;586(7830):488-489
pubmed: 33082543
Viral Immunol. 2018 Mar;31(2):195-203
pubmed: 29336703
PLoS One. 2015 Jun 24;10(6):e0131531
pubmed: 26107625
Int J Obes (Lond). 2017 Sep;41(9):1324-1330
pubmed: 28584297
Clin Immunol. 2018 Aug;193:80-87
pubmed: 29425852
Vaccine. 2016 May 27;34(25):2834-40
pubmed: 27108193
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Autoimmunity. 2006 Mar;39(2):137-41
pubmed: 16698670
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279